About Iptacopan API
Therapeutic CategoryHaematology/Nephrology

CAS Number
1644670‑37‑0
API Technology
Small‑molecule synthetic API
Dose Form
Oral Solid/Capsules
Dr Reddy's Development Status
Under Development
Mechanism of action
Iptacopan binds to complement factor B (FB), a key component of the alternative complement pathway.
This inhibits formation of the C3 convertase (C3bBb), thereby:
Reducing C3 cleavage and C3b generation
Preventing downstream formation of C5 convertase and the membrane attack complex (MAC)
By acting upstream (proximal) in the complement cascade, iptacopan controls:
C3b‑mediated extravascular hemolysis
Terminal complement‑mediated intravascular hemolysis
Importantly, it selectively blocks the alternative pathway, leaving the classical and lectin pathways intact to preserve host immune defense.
Indication
Approved indications (FDA / EMA):
Paroxysmal nocturnal hemoglobinuria (PNH) in adults
Reduction of proteinuria in adults with primary IgA nephropathy (IgAN) at risk of rapid disease progression
Complement 3 glomerulopathy (C3G) to reduce proteinuria
Disclaimer
No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.